Asset
FT-516
Fate Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04551885 | phase1 | terminated | 2020-09-07 | 2023-08-11 | Fate Therapeutics | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors |
| NCT04023071 | phase1 | terminated | 2019-10-04 | 2023-10-23 | Fate Therapeutics | FT516 in Subjects With Advanced Hematologic Malignancies |
FDA applications (0)
This company has no applications containing this asset.